2002
HLA Class II Influences the Immune Response and Antibody Diversification to Ro60/Sjögren’s Syndrome-A: Heightened Antibody Responses and Epitope Spreading in Mice Expressing HLA-DR molecules
Paisansinsup T, Deshmukh US, Chowdhary VR, Luthra HS, Fu SM, David CS. HLA Class II Influences the Immune Response and Antibody Diversification to Ro60/Sjögren’s Syndrome-A: Heightened Antibody Responses and Epitope Spreading in Mice Expressing HLA-DR molecules. The Journal Of Immunology 2002, 168: 5876-5884. PMID: 12023392, DOI: 10.4049/jimmunol.168.11.5876.Peer-Reviewed Original ResearchConceptsHLA class II genesImmune responseCell epitopesB-cell epitopesDQ6 miceDQ8 miceSjögren's syndromeClass II genesDominant T cell epitopesMurine class II moleculesSystemic lupus erythematosusHLA class IISera of patientsB cell responsesDominant B-cell epitopesHLA-DR moleculesT cell epitopesClass II moleculesLupus erythematosusAntibody responseDR3 miceCell responsesHigh titersClass IISyndrome
2000
Sweet's syndrome and Pneumocystis carinii pneumonia: two sequelae of low‐dose cytosine arabinoside therapy in a patient with acute myeloid leukemia
Chowdhary V, Nityanand S, Prasad K, Pandey R, Dabadghao S. Sweet's syndrome and Pneumocystis carinii pneumonia: two sequelae of low‐dose cytosine arabinoside therapy in a patient with acute myeloid leukemia. European Journal Of Haematology 2000, 65: 72-73. PMID: 10914942, DOI: 10.1034/j.1600-0609.2000.9c177.x.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaPneumocystis carinii pneumoniaMyeloid leukemiaCarinii pneumoniaLow‐dose cytosine arabinoside therapyAcute febrile neutrophilic dermatosisAttainment of remissionFebrile neutrophilic dermatosisLow-dose cytosineNeutrophilic dermatosisSweet's syndromeImmunosuppressive potentialNeutrophil functionLow doseLow dosesLeukemiaPneumoniaSyndromeDirect effectRemissionSequelaePatientsDermatosesTherapyDose